On efficacy, at least, BeOne’s BTK degrader shows an edge.
ApexOnco Front Page
Recent articles
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.
But first it will need to identify the optimal dose in first-line small-cell lung cancer.
But results come from a curated dataset, with no in-trial comparator.
The latest projects newly into human trials include BNT3212.
Global data are in the same ballpark as Chinese results presented earlier this year.
